Chronic Myeloid Leukemia News and Research

RSS
Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.
MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

John Theurer Cancer Center presents research findings at ASH meeting

John Theurer Cancer Center presents research findings at ASH meeting

New drug appears to help patients with chronic myeloid leukemia

New drug appears to help patients with chronic myeloid leukemia

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Rush University enrolls first U.S. patient in international clinical trial for melanoma

Rush University enrolls first U.S. patient in international clinical trial for melanoma

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

ARIAD reports $20.4 million net loss for third quarter 2010

ARIAD reports $20.4 million net loss for third quarter 2010

CytRx reports $4.4 million net loss for third quarter 2010

CytRx reports $4.4 million net loss for third quarter 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

New microfluidic in vitro kinase radioassay improves efficiency to detect cancer growth

New microfluidic in vitro kinase radioassay improves efficiency to detect cancer growth

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

Immune system may play a role in cancer therapies: Study

Immune system may play a role in cancer therapies: Study